Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Here’s Why

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw an uptick in trading volume on Wednesday . 3,028 shares traded hands during trading, a decline of 7% from the previous session’s volume of 3,243 shares.The stock last traded at $26.16 and had previously closed at $23.87.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Thursday, March 26th. Rodman & Renshaw started coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target for the company. Finally, Oppenheimer began coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Stock Up 9.9%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The company has a 50 day simple moving average of $23.90 and a two-hundred day simple moving average of $29.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million for the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter valued at about $383,000. XY Capital Ltd boosted its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the last quarter. UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International during the 3rd quarter valued at approximately $204,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International in the 3rd quarter worth approximately $96,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.